临床试验

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT：NCT02876042 · COMPLETED

NCT编号NCT02876042

状态COMPLETED

开始日期2017-03-23

完成时间2025-11-03

SponsorCVRx, Inc. (INDUSTRY)

First posted2016-08-23

Last updated2026-09-11

简要摘要

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。